SCHEMBL3597208

SCHEMBL3597208

O=C(/C=C1\CC2(COC2)Oc2cc(C(F)(F)F)ccc21)Nc1cccc2c1CNC(=O)N2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 9/20 0.39
KDR P35968 4/20 0.34
DHPS P49366 1/20 0.31
PLK4 O00444 1/20 0.31
ROCK2 O75116 1/20 0.31
NTRK1 P04629 1/20 0.31
MET P08581 1/20 0.31
ROS1 P08922 1/20 0.31
RPS6KB1 P23443 1/20 0.31
EPHA2 P29317 1/20 0.31
AXL P30530 1/20 0.31
FLT4 P35916 1/20 0.31
FLT3 P36888 1/20 0.31
FRK P42685 1/20 0.31
MAPK9 P45984 1/20 0.31
IRAK1 P51617 1/20 0.31
ROCK1 Q13464 1/20 0.31
NTRK2 Q16620 1/20 0.31
TAOK1 Q7L7X3 1/20 0.31
HIPK4 Q8NE63 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3588809 0.93 TRPV1 (0.37) TRPV1KDR
SCHEMBL3595505 0.93 TRPV1 (0.38) TRPV1KDRHDAC3HDAC4HDAC1
SCHEMBL4449065 0.91 TRPV1 (0.42) TRPV1KDRHDAC3HDAC4HDAC1
SCHEMBL3598279 0.89 TRPV1 (0.46) TRPV1KDRTP53
SCHEMBL4456828 0.88 TRPV1 (0.38) TRPV1DHPS
SCHEMBL3598839 0.87 TRPV1 (0.48) TRPV1KDR
SCHEMBL3592737 0.85 TRPV1 (0.41) TRPV1KDRTP53
SCHEMBL3588260 0.83 TRPV1 (0.43) TRPV1KDR
SCHEMBL3606745 0.83 TRPV1 (0.41) TRPV1
SCHEMBL3597017 0.83 TRPV1 (0.32) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 TRPV1 2518/4885KDR 2461/4885DHPS 3506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.